• President Trump's remark that Israel will have the option to buy weapons 'whatever they want' underscores continued U.S. support for Israel's military access, but stops short of a new aid package.
  • Discussions are underway for a successor to the current $38 billion aid agreement, with Israel proposing to phase out direct grants in favor of joint production and research.
  • Recent arms sale notifications exceeding $12 billion in 2025 and a reported $2.8 billion munitions package signal robust purchasing activity, yet the financing model remains unresolved.

President Trump's statement that Israel will have the option to buy weapons 'whatever they want' is being read as a signal of continued U.S. commitment to Israel's security, but it does not by itself alter the financial architecture of American military assistance. The distinction between permission to purchase and a commitment to fund is central: the U.S. is not currently obligated to pay for arms Israel may want to acquire beyond the terms of the existing aid agreement, which runs through 2028.

Behind the headline, a quiet but consequential negotiation is taking shape. According to the Congressional Research Service, Washington and Jerusalem have begun discussing a successor to the 2016 Memorandum of Understanding, which pledges $38 billion over fiscal years 2019–2028—$33 billion in Foreign Military Financing grants and $5 billion for missile defense. Israeli officials, including Prime Minister Netanyahu, have floated a gradual replacement of direct grants with joint research, development, and weapons production. No replacement agreement has been finalized, and the proposal remains just that—a proposal.

Meanwhile, weapons sales are proceeding at a brisk clip. An October 7 CRS report notes that the administration formally notified Congress of possible Israeli arms sales exceeding $12 billion in 2025 and reportedly more than $7 billion in additional potential sales during 2026. These figures represent proposed-sale values, not deliveries or new appropriations. Separately, Reuters (NASDAQ:TRI) reported in September that the administration was planning a $2.8 billion munitions package, including 20,000 MK-84 and 20,000 BLU-117 bombs, which had been informally communicated to congressional committees at the time.

The Financing Puzzle

The economic implications hinge on which funding model prevails. If grants are phased out in favor of Israeli-funded purchases, Israel's government would shoulder more procurement costs unless offset by other arrangements. U.S. defense manufacturers, which have benefited from grant-financed purchases, could still see demand if purchasing access continues—but actual orders would depend on Israeli funding and U.S. approvals. Israel's domestic defense industry might gain opportunities from a shift toward joint production, while U.S. taxpayers could see lower direct assistance spending, though the net effect would depend on replacement commitments for missile defense and research.

'Whatever they want' should be interpreted as political rhetoric rather than a legal carte blanche. Arms transfers remain bound by U.S. law and congressional oversight. The administration has previously invoked emergency authority under Section 36(b) of the Arms Export Control Act to bypass the standard congressional review period for nearly $4 billion in Israeli arms sales in February 2025. Congress remains a wild card: ahead of the November 3 midterms, reporting indicated growing Democratic support for restricting aid or specific weapon types, though election outcomes were not established at the time of this writing.

The broader context is one of continuity punctuated by debate. Since the October 7, 2023 Hamas attacks, the U.S. has approved tens of billions in new Israeli arms sales financed through military assistance. The current aid agreement also phases out Israel's special ability to spend part of that aid on domestically produced weapons, tying more grant-funded procurement to U.S. suppliers. There is precedent for policy shifts without a rupture in the alliance: the Biden administration withheld some weapons over concerns about their use, while the Trump administration subsequently released shipments and accelerated transfers.

In the near term, the meaningful indicators will be formal sale notifications, funding sources, signed purchase agreements, and delivery schedules—not the headline's wording. The reported $2.8 billion munitions proposal is one concrete transaction to monitor. Over the longer term, the post-2028 agreement is the more consequential issue. It could preserve grants, phase them down, or emphasize joint technology and production. As CRS cautions, financial independence would not quickly translate into operational independence from U.S. equipment and support.

A connected geopolitical development adds urgency: the U.S. conducted defensive strikes against Iranian targets in the Strait of Hormuz while diplomatic contacts continued, according to the Associated Press. That regional security backdrop matters to weapons demand and U.S.-Israel coordination, but it does not establish the timing or purpose of the quoted remark.

The unresolved question is therefore not simply whether Israel can buy American weapons. It is how future purchases will be funded, what conditions Congress and the administration will attach, and how much the partnership shifts from grants toward joint production. For now, the headline signals openness—but the checkbook remains a work in progress.